Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents

Abstract

Patients experiencing stroke or transient ischemic attack (TIA) are at high risk for recurrent (secondary) strokes, which comprise 29% of all strokes in the United States. Current recommendations for prevention of secondary stroke from the American College of Chest Physicians (ACCP) call for the broad use of platelet antiaggregation (antiplatelet) agents for patients with a history of noncardioembolic stroke or TIA. Five agents—aspirin, ticlopidine, clopidogrel, extended-release dipyridamole (ER-DP), and triflusal—have demonstrated efficacy in large-scale clinical studies in the prevention of recurrent vascular events and/or stroke in patients with a history of stroke. The results of the following studies are reviewed and compared: the Swedish Aspirin Low-Dose Trial (SALT), the United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial, Dutch Transient Ischemic Attack (Dutch TIA) study (aspirin), the Canadian American Ticlopidine Study (CATS), the Ticlopidine Aspirin Stroke Study (TASS), the African American Antiplatelet Stroke Prevention Study (AAASPS) (ticlopidine), the Clopidogrel versus Aspirin in Patients at Risk of Recurrent Ischemic Events (CAPRIE) trial, the Management of Atherothrombosis With Clopidogrel in High-Risk Patients study (MATCH) (clopidogrel), the second European Stroke Prevention Study (ESPS2) (aspirin plus ER-DP), and the Triflusal versus Aspirin in Cerebral Infarction Prevention (TACIP) study. In comparative monotherapy studies of patients with previous stroke, ticlopidine demonstrates statistically significant improved efficacy over aspirin, and clopidogrel demonstrates nonsignificant slight improvement over aspirin for the prevention of ischemic cardiac and cerebrovascular events; however, the adverse event profile of ticlopidine (including rash, diarrhea, and neutropenia) will probably limit its long-term use. Among combination approaches, only aspirin plus ERDP has demonstrated statistically significant, clinically meaningful additive benefit over monotherapy with each agent. Clopidogrel plus aspirin did not significantly improve preventive efficacy and increased the risk of serious side effects, including life-threatening bleeding episodes. The 15,500-patient PRoFESS (the Prevention Regimen for Effectively Avoiding Second Strokes) study, with results expected in 2008, will directly compare aspirin plus ER-DP with clopidogrel monotherapy for the prevention of recurrent stroke and should provide statistically robust estimates of comparative efficacy for the development of improved recommendations.

Keywords

recurrent stroke clopidogrel aspirin ticlopidine extended-release dipyridamole triflusal

References

American Heart Association . Heart Disease and Stroke Statistics—2005 Update. Dallas, Tex: American Heart Association, 2005

Sacco RL , Wolf PA , Kannel WB , et al . Survival and recurrence following stroke. The Framingham study. Stroke 13:290-295, 1982

Petty GW , Brown RD Jr , Whisnant JP , et al . Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50:208-216, 1998

Coull AJ , Rothwell PM . Underestimation of the early risk of recurrent stroke: Evidence of the need for a standard definition. Stroke 35:1925-1929, 2004

Lovett JK , Coull AJ , Rothwell PM . Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62:569-573, 2004

Blake GJ , Ridker PM . Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252:283-294, 2002

Ridker PM , Stampfer MJ , Rifai N . Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481-2485, 2001

Decline in deaths from heart disease and stroke-United States, 1900-1999 . MMWR Morb Mortal Wkly Rep 48:649-656, 1999

Gillum RF , Sempos CT . The end of the long-term decline in stroke mortality in the United States? Stroke 28:1527-1529, 1997

10.

Vickrey BG , Rector TS , Wickstrom SL , et al . Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33:901-906, 2002

11.

Albers GW , Amarenco P . Combination therapy with clopidogrel and aspirin: Can the CURE results be extrapolated to cerebrovascular patients? Stroke 32:2948-2949, 2001

12.

Albers GW . Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients? Neurology 54:1022-1028, 2000

13.

Albers GW , Amarenco P , Easton JD , et al . Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:483S-512S, 2004

14.

Dorsam RT , Kunapuli SP . Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113:340-345, 2004

15.

Quinn MJ , Fitzgerald DJ . Ticlopidine and clopidogrel. Circulation 100:1667-1672, 1999

16.

Aggrenox (aspirin/extended-release dipyridamole) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2003

17.

Brass LF . More pieces of the platelet activation puzzle slide into place. J Clin Invest 104:1663-1665, 1999

18.

Offermanns S , Rosenthal W , eds. Encyclopedic Reference of Molecular Pharmacology. New York, NY: Springer; 2004

19.

Sanmuganathan PS , Ghahramani P , Jackson PR , et al . Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85:265-271, 2001

20.

A randomized trial of aspirin and sulfinpyrazone in threatened stroke . The Canadian Cooperative Study Group . N Engl J Med 299:53-59, 1978

21.

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke . The Dutch TIA Trial Study Group . N Engl J Med 325:1261-1266, 1991

22.

Farrell B , Godwin J , Richards S , et al . The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 54:1044-1054, 1991

23.

Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events . The SALT Collaborative Group . Lancet 338:1345-1349, 1991

24.

Awtry EH , Loscalzo J . Aspirin. Circulation 101:1206-1218, 2000

25.

Gent M , Blakely JA , Easton JD , et al . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1:1215-1220, 1989

26.

Hass WK , Easton JD , Adams HP Jr , et al . A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321:501-507, 1989

27.

Gorelick PB , Richardson D , Kelly M , et al . Aspirin and ticlopidine for prevention of recurrent stroke in black patients: A randomized trial. JAMA 289:2947-2957, 2003

28.

Bennett CL , Weinberg PD , Rozenberg-Ben-Dror K , et al . Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128:541-544, 1998

29.

Bennett CL , Connors JM , Carwile JM , et al . Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 342:1773-1777, 2000

30.

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) . CAPRIE Steering Committee . Lancet 348:1329-1339, 1996

31.

Diener HC , Bogousslavsky J , Brass LM , et al . Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebocontrolled trial. Lancet 364:331-337, 2004

32.

Sivenius J , Riekkinen PJ , Smets P , et al . The European Stroke Prevention Study (ESPS): Results by arterial distribution. Ann Neurol 29:596-600, 1991

33.

Diener HC , Cunha L , Forbes C , et al . European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13, 1996

34.

Albers GW , Amarenco P , Easton JD , et al . Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 119:300S-320S, 2001

35.

Matias-Guiu J , Ferro JM , Alvarez-Sabin J , et al . Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: The TACIP study: A randomized, double-blind, multicenter trial. Stroke 34(4):840-848, 2003